First patient in treatment in RhoVac’s clinical phase IIb study in the USA
Dr. Neal D. Shore has been invited to join the prestigious Duke Global Health Institute Board of Advisors
The inaugural board of advisors for Duke Global Health Institute, founded in 2009, was composed of 14 visionary members who embraced Duke’s vision to build a world-class program that would lead its peers in the charge to address global health disparities. The work of that group played a vital role in developing DGHI into the establishment it is today, with over 400 students and 100 faculty from 8 Duke schools, conducting research in over 40 countries.
The DGHI board of advisors is entering its own phase of growth, from 15 to 25 members over the next five years. DGHI values board service and seeks to: 1) cultivate members’ interest in global health by providing opportunities for learning, meaningful discourse and interaction with leaders in the field; 2) honor its members’ contribution of time and effort by enlisting guidance and expertise on matters for which they can be most impactful; 3) foster in its members a sense of inspiration and purpose by facilitating interaction with students, faculty and staff; and 4) create an experience that deepens members’ affinity and connection to Duke University.
In creating a positive and engaging board experience, DGHI aims to empower its advisory board members to serve in a variety of ways: as thought partners, champions, investors and ambassadors who facilitate relationships and opportunities that support its mission. The DGHI advisory board convenes twice annually, once in the spring and another in the fall. Spring meetings rotate between New York, NY and Washington, DC; and fall meetings meet in Durham, NC. Terms of service last three years, and are renewable once by mutual agreement.
Dr. Shore’s educational and professional background, philanthropic investments, and alumnus status made him a fortuitous addition.
Presented by: Neal D. Shore, Paul F. Schellhammer, Ronald F. Tutrone, Neil F. Mariados, Stacey S. Harrelson
Johann de Bono, M.B., Ch.B., Ph.D., Joaquin Mateo, M.D., Ph.D., Karim Fizazi, M.D., Ph.D., Fred Saad, M.D., Neal Shore, M.D., Shahneen Sandhu, M.D., Kim N. Chi, M.D., Oliver Sartor, M.D., Neeraj Agarwal, M.D., David Olmos, M.D., Ph.D., Antoine Thiery-Vuillemin, M.D., Ph.D., Przemyslaw Twardowski, M.D., et al.
Neal D. Shore, M.D., Fred Saad, M.D., Michael S. Cookson, M.D., M.M.H.C., Daniel J. George, M.D., Daniel R. Saltzstein, M.D., Ronald Tutrone, M.D., Hideyuki Akaza, M.D., Alberto Bossi, M.D., David F. van Veenhuyzen, M.B., Ch.B., M.Pharm.Med., Bryan Selby, M.S., Xiaolin Fan, Ph.D., Vicky Kang, M.D., et al., for the HERO Study Investigators*
Presented by: Cora N. Sternberg, M.D., Karim Fizazi, M.D., Ph.D., Fred Saad, M.D., Neal D. Shore, M.D., Ugo De Giorgi, M.D., Ph.D., David F. Penson, M.D., M.P.H., Ubirajara Ferreira, M.D., Ph.D., Eleni Efstathiou, M.D., Ph.D., Katarzyna Madziarska, M.D., Ph.D., Michael P. Kolinsky, M.D., Daniel I. G. Cubero, M.D., Ph.D., Bettina Noerby, M.D., et al., for the PROSPER Investigators*
Presented by: Johann de Bono, M.B., Ch.B., Ph.D., Joaquin Mateo, M.D., Ph.D., Karim Fizazi, M.D., Ph.D., Fred Saad, M.D., Neal Shore, M.D., Shahneen Sandhu, M.D., Kim N. Chi, M.D., Oliver Sartor, M.D., Neeraj Agarwal, M.D., David Olmos, M.D., Ph.D., Antoine Thiery-Vuillemin, M.D., Ph.D., Przemyslaw Twardowski, M.D., et al.
Presented by: Neal Shore, MD, FACS, Medical Director of the Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, South Carolina
Neal D. Shore, Daniel Saltzstein, Paul Sieber, Bryan Mehlhaff, Lawrence Gervasi, Jennifer Phillips, Yu-Ning Wong, Huiling Pei, Tracy McGowan
- Perioperative Pembrolizumab Therapy In Muscle-Invasive Bladder Cancer: Phase III KEYNOTE-866 And KEYNOTE-905/EV-303
- Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia
- Efficacy of Enzalutamide Plus Androgen Deprivation Therapy In Metastatic Hormone-Sensitive Prostate Cancer By Pattern of Metastatic Spread: ARCHES Post Hoc Analyses
- Comparison of Germline Mutations In African American And Caucasian Men With Metastatic Prostate Cancer